Dr. VK Paul, Member (Health), NITI Aayog, has told today that the Drug Controller General of India (DCGE) has approved covaxin for Phase II and Phase III clinical trials for the age group of 2 to 18 years. NITI Aayog have been told that trials will begin in the next 10-12 days.
The Drugs Controller General of India has approved the second and third phase of clinical trials of covaxin in the 2-18 age group last week. India will conduct biotech covaxin trials on 525 healthy volunteers. Clinical trials will be done at AIIMS in Delhi and Patna and at the Meditrina Institute of Medical Sciences, Nagpur.